Seoul Pharma서울제약
018680 · KOSDAQ · ₩018680 · 서울제약
- Market cap
- ₩22B
- Enterprise value
- ₩8.3B
- P/E
- 12.7×
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- 4.3%
- Net margin
- 3.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−42.6% from the high
₩1,750Today: ₩1,855 – ₩2,000₩3,310
Returns
- 1W+1.0%
- 1M−2.5%
- 3M−4.5%
- 6M−33.3%
- YTD−38.3%
- 1Y−39.7%
- Volume today
- 644
- 0.1× the 20-day average
- Traded today
- ₩1.2M
- Listed shares
- 11,659,319
- EPS (12 months)
- ₩149
- Earnings yield 7.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumFlat-2.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Seoul Pharma stock overview
Seoul Pharma (서울제약, KRX: 018680) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells prescription pharmaceutical products in South Korea, operating as a single business segment in pharmaceutical manufacturing. Its shares closed at ₩1,899 on Oct 27, 2026, down 0.05% on the day, giving it a market value of ₩22B.
Key facts
- Market cap
- ₩22B
- Sector
- Biotech & Pharma
- Latest price change
- −0.05%
- As of
- Oct 27, 2026
- Main business
- The company develops, manufactures and sells prescription pharmaceutical products in South Korea, operating as a single business segment in pharmaceutical manufacturing.
Quick answers about Seoul Pharma
- What does Seoul Pharma do?
- The company develops, manufactures and sells prescription pharmaceutical products in South Korea, operating as a single business segment in pharmaceutical manufacturing. Its main products include the Oklatin antibiotic line, the Cresten and Atorr cardiovascular and lipid treatments, and orally disintegrating films based on its SmartFilm Technology for chronic disease treatment. The company operates a cGMP-standard plant in Osong, Korea, and aims to expand into advanced markets such as the United States.
- What is the market cap of Seoul Pharma?
- The market capitalisation of Seoul Pharma was ₩22B at the close on Oct 27, 2026.
- Who are the largest shareholders of Seoul Pharma?
- According to the latest official filings, the largest reported holders are 2018 QCP No. 13 Private Equity Fund (59.48%, as of Apr 1, 2026); Shin Bong-hwan (0.07%, as of Mar 27, 2026).
- When is the next earnings report from Seoul Pharma?
- Korean companies rarely announce results dates in advance. Based on when Seoul Pharma filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops, manufactures and sells prescription pharmaceutical products in South Korea, operating as a single business segment in pharmaceutical manufacturing. Its main products include the Oklatin antibiotic line, the Cresten and Atorr cardiovascular and lipid treatments, and orally disintegrating films based on its SmartFilm Technology for chronic disease treatment. The company operates a cGMP-standard plant in Osong, Korea, and aims to expand into advanced markets such as the United States.
Written by AI from the company's latest annual report.
- Korean name
- 서울제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- Business group
- QCP
- CEO
- 윤동현, 신봉환 (각자대표)
- Founded
- Dec 1985
- Listed
- Aug 2000
- Listed shares
- 11,659,319
- Fiscal year ends
- Month 12
- Website
- www.seoulpharma.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 28, 2026
- Results of Extraordinary Shareholders' MeetingAug 21, 2026
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation BodiesAug 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Notice of shareholders' meetingAug 6, 2026
Titles in Korean until English translations are added.
Also known as: Seoul Pharma / 서울제약 / 018680 / KRX:018680
Source: KRX statistical information